Quest Diagnostics
711 hedge funds and large institutions have $12.8B invested in Quest Diagnostics in 2019 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 249 increasing their positions, 234 reducing their positions, and 43 closing their positions.
116% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 43
42% more call options, than puts
Call options by funds: $51.1M | Put options by funds: $35.9M
5% more funds holding
Funds holding: 676 → 711 (+35)
6% more repeat investments, than reductions
Existing positions increased: 249 | Existing positions reduced: 234
0.28% less ownership
Funds ownership: 89.22% → 88.94% (-0.28%)
0% less capital invested
Capital invested by funds: $12.8B → $12.8B (-$50.2M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bessemer Group
Woodbridge,
New Jersey
|
+$53.3M |
| 2 |
JP Morgan Chase
New York
|
+$43.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$39.2M |
| 4 |
Goldman Sachs
New York
|
+$32.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$167M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$68.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$58.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$36M |
| 5 |
Millennium Management
New York
|
-$35M |
DGX Hedge Fund Activity: Q4 2019 in Review
711 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q4 2019, worth a combined $12.8B — down 0.39% from $12.8B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new DGX positions and 43 closed out — a net gain of 50 holders — while 249 added to existing stakes and 234 trimmed.
The largest buyer was Bessemer Group, adding an estimated $53.3M. The largest seller was Boston Partners, cutting an estimated $167M.
- 711 institutional investors held Quest Diagnostics (DGX) as of Q4 2019, up from 676 in Q3 2019.
- Funds reported $12.8B of Quest Diagnostics stock for Q4 2019, down 0.39% quarter-over-quarter.
- 93 funds opened new Quest Diagnostics positions in Q4 2019 and 43 closed out, a net change of +50 holders.
- The largest Quest Diagnostics buyer in Q4 2019 was Bessemer Group, an estimated $53.3M added.
- The largest Quest Diagnostics seller in Q4 2019 was Boston Partners, an estimated $167M sold.
Based on aggregated 13F filings for Q4 2019.